A manifesto for Alzheimer’s disease drug discovery in the era of disease-modifying therapies

A manifesto for Alzheimer’s disease drug discovery in the era of disease-modifying therapies

Abstract After decades of disappointment, three disease-modifying therapies for Alzheimer’s disease (AD) have been approved since 2021. Burgeoning clinical data on these amyloid β-protein (Aβ) targeting drugs validate the amyloid cascade hypothesis as a molecular roadmap for the development of yet m...

Full description

Saved in:
Bibliographic Details
Main Authors: Heike Hering, Thierry Bussiere, Chia-Chen Liu, Kelly E. Glajch, Andreas Weihofen, Jane Grogan, Dominic M. Walsh
Format: Article
Language:English
Published: BMC 2025-08-01
Series:Molecular Neurodegeneration
Subjects:
Aggregation inhibitors
⍺-synuclein
Amyloid β-protein
Antisense oligonucleotides
Apolipoprotein E
Brain shuttles
Online Access:https://doi.org/10.1186/s13024-025-00872-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13024-025-00872-7

Similar Items